Accelerating Advancements in Women's Health - LOI Req

Letter of Intent Deadline: 

Jun 20, 2023


Myovant Sciences & Pfizer

UI Contact: 

See complete details about this RFP (pdf). Full proposals due in September.

The intent of this Request for Proposal (RFP) is to support research in the following areas:

  • Rel-CT as preoperative therapy and/or for surgery avoidance
  • Rel-CT effect on uterine fibroids prior to surgical intervention (e.g.: alteration of dissection planes in myomectomy, fibroid shrinkage, etc.)
  • Rel-CT in conjunction with surgery
  • Rel-CT in patients with infertility
  • Rel-CT and health-related quality of life (HRQOL), patient reported outcomes (PROs), or patient satisfaction in estrogen-driven diseases
  • Examination of patient preference and health disparities on medical vs surgical options for management of UF/EM
  • Rel-CT and UF- or EM-related healthcare utilization including but not limited to hospitalizations, office visits, emergency department visits, cost to patients, and absenteeism
  • Rel-CT and premenstrual dysphoric disorder (PMDD)
  • Rel-CT and female sexual dysfunction
  • Rel-CT for heavy menstrual bleeding of idiopathic etiology (excludes uterine fibroids, endometriosis, and adenomyosis)
  • Rel-CT use in perimenopausal patients
  • Rel-CT for pelvic pain of idiopathic etiology
  • Rel-CT for induction of amenorrhea

Relugolix Combination Therapy [Rel-CT], commercially available as Myfembree®, is a fixeddose combination of relugolix (a gonadotropin-releasing hormone receptor antagonist) estradiol, and norethindrone acetate. It is a once-daily oral medication indicated in premenopausal women for the management of heavy menstrual bleeding associated with uterine leiomyomas or for moderate to severe pain associated with endometriosis